<DOC>
	<DOCNO>NCT01090440</DOCNO>
	<brief_summary>GSK1144814 potent , insurmountable antagonist human neurokinin-1 ( NK1 ) neurokinin-3 ( NK3 ) receptors potential treat multiple symptom domain schizophrenia efficacious antidepressant . This study open label , randomise , three-way cross-over study evaluate safety , tolerability pharmacokinetics new tablet formulation GSK1144814 evaluate effect food single oral dos GSK1144814 healthy male female subject .</brief_summary>
	<brief_title>Pharmacokinetics , Effect Food , Safety Tolerability New Tablet Formulation GSK1144814 Healthy Subjects</brief_title>
	<detailed_description>GSK1144814 potent , insurmountable antagonist human neurokinin-1 ( NK1 ) neurokinin-3 ( NK3 ) receptors potential treat multiple symptom domain schizophrenia efficacious antidepressant . This study open label , randomise , three-way cross-over study evaluate safety , tolerability pharmacokinetics new tablet formulation GSK1144814 evaluate effect food single oral dos GSK1144814 healthy male female ( non-child bearing potential ) subject . The study consist Screening visit ( 30 day first dose session ) , three dose session separate maximum least 6 day washout , Follow visit ( 7 14 day last dose study medication ) . Each subject 's participation study approximately 12 week Sixteen subject enrol provide minimum number 12 evaluable subject . The dos administer 100 mg 200mg fasted state , 100mg follow high fat breakfast . Subjects admitted unit Day 1 dose session remain unit 48 hour dose . Pharmacokinetic sample take 72 hour post dose . The duration patient stay PK sampling may subject change depend emerge safety PK result . Dosing morning approximately time session . The objective study evaluate pharmacokinetics , safety tolerability GSK1144814 . Pharmacokinetic objective evaluate pharmacokinetic parameter single oral dos GSK1144814 administer tablet formulation healthy male female subject evaluate effect high-fat meal pharmacokinetics GSK1144814 tablet follow single dose administration GSK1144814 healthy male female subject . The safety tolerability objective evaluate safety tolerability single oral dos GSK1144814 tablet formulation feed fasted state .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Healthy determine responsible physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinically significant abnormality laboratory parameter significantly outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male female 18 65 year age . A female subject eligible participate : Non childbearing potential define pre menopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea ( questionable case blood sample simultaneous follicle stimulate hormone [ FSH ] great 40 mIU/mL oestradiol le 40 pg/mL [ le 140 pmol/L ] confirmatory ) . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require discontinue HRT allow confirmation post menopausal status prior study enrolment . For form HRT , least 2 4 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation post menopausal status , resume use HRT study without use contraceptive method . Male subject must agree use one contraception method alloed protocol . This criterion must follow first dose day 3 month last dose . Body weight great equal 50 kg BMI within range 19 29.9 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . Demonstrates evidence mental impairment comorbid psychiatric disorder History presence clinically significant cardiac arrhythmia , clinically significant cardiac disease . QTcB QTcF great 450 msec . Subjects , investigator 's judgement , pose significant suicide risk . Evidence serious suicide risk may include history suicidal behavior and/or suicidal ideation type 4 5 CSSRS last 6 month . The subject positive pre study drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . A positive pre study hepatitis B surface antigen ( HBsAg ) positive hepatitis C virus ( HCV ) antibody test result within 3 month Screening . A positive test result antibody human immunodeficiency virus ( HIV ) 1/2 . Significant renal abnormality ( medical history indicate laboratory investigation ) . Additionally subject idiopathic haematuria proteinuria condition benign orthostatic proteinuria benign familial haematuria exclude study . Urinary cotinine level indicative smoke history regular use tobacco nicotine containing product within 6 month prior Screening . Subjects , investigator 's judgement , pose significant homicidal risk ever homicidal . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription non prescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 half life ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History regular alcohol consumption within 6 month study define follow Australian guideline : An average weekly intake great 21 unit average daily intake great 3 unit ( male ) , defined average weekly intake great 14 unit average daily intake great 2 unit ( female ) . One unit equivalent 270ml full strength beer , 470ml light beer , 30ml spirit 100ml wine . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Unwillingness inability follow procedure outline protocol . Consumption Seville orange ( include marmalade ) and/or grapefruit and/or Chinese grapefruit ( pomelo ) and/or grapefruit hybrid and/or exotic citrus fruit and/or fruit juice 7 day prior first dose day . Consumption red wine 7 day prior first dose day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>GSK1144814</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>effect food</keyword>
	<keyword>depressive disorder</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>healthy subject</keyword>
</DOC>